Patient Rating:

4.7 out of 5

29 Patient Ratings
10 Patient Comments

Alfred K. Cheung, M.D.

Chief, Division of Nephrology

Patient Rating:

4.7 out of 5

29 Patient Ratings
10 Patient Comments

Specialties

Languages

  • Cantonese
  • English

Clinical Details

Phone Number Clinical Office Address
(801) 585-6320
University Hospital
Kidney and Liver Clinic
50 N Medical Dr , Suite A100
Salt Lake City, UT 84132
Map

Bio

Alfred K. Cheung, M.D. is a Professor of Medicine, Chief of Division of Nephrology & Hypertension and Executive Director of the Dialysis Program at the University of Utah Hospital & Clinics. As a nephrologist, he manages a variety of kidney diseases, with particular interests in chronic kidney disease, hypertension and chronic dialysis. He is active in research and speaks frequently at a national level in these areas. Dr. Cheung received his M.D. degree from Albany Medical College in New York. He completed his Nephrology fellowship training from the University of California at San Diego. He is board certified in Internal Medicine and Nephrology. Dr. Cheung has been active on various committees in the American Society of Nephrology and National Kidney Foundation. He has also co-chair national practice guidelines.

Board Certification and Academic Information

Academic Departments Internal Medicine - Professor
Pharmaceutics and Pharmaceutical Chemistry - Adjunct Professor
Academic Divisions Nephrology
Board Certification American Board of Internal Medicine (Sub: Nephrology)
National Board of Medical Examiners
American Board of Internal Medicine (Internal Medicine)

Patient Ratings

The Patient Rating score is an average of all responses to care provider related questions on our nationally-recognized Press Ganey Patient Satisfaction Survey.

Responses are measured on a scale of 1 to 5 with 5 being the best score.

Likelihood of recommending care provider
4.7
My confidence in care provider
4.8
Time care provider spent with me
4.5
Care provider spoke using clear language
4.6
Care provider's effort to include me in decisions
4.7
Care provider's concern for questions & worries
4.7
Care provider's explanation of condition/problem
4.7
Wait time at clinic
Care provider's friendliness and courtesy
4.8

Patient Comments

Patient comments are gathered from our Press Ganey Patient Satisfaction Survey and displayed in their entirety. Patients are de-identified for confidentiality and patient privacy.

March 04, 2016

Enjoy visits

January 08, 2016

Good experience.

June 16, 2015

Dr. Cheung was so thorough, and not rushed, while treating me at my new patient appointment. He provided all kinds of information, and continually asked me if I had any questions. He was kind, and he let me talk and get all of my worries out.

April 08, 2015

Very informative

October 11, 2014

Routine visit.

October 07, 2014

Dr. Cheung is fantastic.

April 25, 2014

Short, pleasant, routine visit.

February 09, 2014

Dr. Cheung always trys to make his time avaialble for me though he is a very busy person. Sometimes, however, we have to communicate with him through his PA, nurse, or secretary and it is not always easy or communicate accurately throgh them.

October 28, 2013

Same as previous visits. Dr. sometimes rushed because of need to input data during visit.

August 26, 2013

very good

Academic Profile

Board Certification and Academic Information

Academic Departments Internal Medicine - Professor
Pharmaceutics and Pharmaceutical Chemistry - Adjunct Professor
Academic Divisions Nephrology
Board Certification American Board of Internal Medicine (Sub: Nephrology)
National Board of Medical Examiners
American Board of Internal Medicine (Internal Medicine)

Academic Office Locations

Academic Office Phone Number Academic Office Address
(801) 585-5215 Ezekiel R & Edna Dumke Building
Division of Nephrology & Hypertension
85 N Medical Drive East
Salt Lake City, UT 84112

Academic Bio

Alfred K. Cheung, M.D. is a Professor of Medicine, Chief of Division of Nephrology & Hypertension and Executive Director of the Dialysis Program at the University of Utah Hospital & Clinics. He holds the inaugural Dialysis Research Foundation endowed chair. Dr. Cheung received his M.D. degree from Albany Medical College in New York. He completed his Nephrology fellowship training from the University of California at San Diego. He is a translational laboratory and clinical investigator in the areas of chronic kidney disease, hemodialysis and hypertension and receives his research funding primarily from the NIH. His research laboratory has been active in training graduate students and post-doctoral fellows. He participates in various scientific functions sponsored by the NIH, American Society of Nephrology and National Kidney Foundation.

Education

Education History

Type School Degree
Fellowship University of California - San Diego
Research Nephrology
Fellow
Fellowship University of California - San Diego
Clinical Nephrology
Fellow
Residency Loma Linda University
Internal Medicine
Resident
Internship Loma Linda University
Intern
Professional Medical Albany Medical College
Medicine
M.D.
Undergraduate State University of New York
B.A.

Publications

Selected Provider Publications

Journal Article

  1. Wright JT, Williamson JD, Whelton PK, Snyder JK, Sink KM, Rocco MV, Reboussin DM, Mahboob Rahman M, Oparil S, Lewis CE, Kimmel PL, Johnson KC, Goff DC, Fine LJ, Cutler JA, Cushman WC, Cheung AK, Ambrosius WT, for the SPRINT Study Research Group (01/01/2015). A randomized trial of intensive versus standard blood pressure control. N Engl J Med.
  2. Rivara MB, Soohoo M, Streja E, Molnar MZ, Rhee C, Cheung AK, Katz R, Arah OA, Nissenson AR, Himmelfarb J, Kalantar-Zadeh K, Mehrotra R (01/01/2015). Association of vascular access type with mortality, hospitalization, and transfer to in-center hemodialysis in patients undergoing home hemodialysis. in press. Clin J Am Soc Nephrol.
  3. Jovanovich AJ, Chonchol MB, Sobhi A, Kendrick JB, Cheung AK, Kaufman JS, Smits G, Jablonski KL and the HOST Investigators (01/01/2015). Mineral metabolites, angiotensin II inhibition, and outcomes in advanced chronic kidney disease. in press. Am J Nephrol.
  4. Mehrotra R, Soohoo M, Rivara M, Himmelfarb J, Cheung AK, Arah OA, Nissenson A, Ravel V, Streja E, Kuttykrishnan S, Katz R, Molnar MZ, Kalantar-Zadeh K (01/01/2015). : Racial and ethnic disparities in utilization of and outcomes with home dialysis in the United States. J Am Soc Nephrol, in press. J Am Soc Nephrol.
  5. Terry CM, Zhuplatov I, He Y, Wun TC, Kim SE, Cheung AK (01/01/2015). Assessment of novel anti-thrombotic fusion proteins for inhibition of stenosis in a porcine model of arteriovenous graft. (PMID: 26360605). PLoS ONE.
  6. Yan G, Cheung AK, Greene T, Yu AJ, Oliver MN, Yu W, Ma JZ, Norris KC (01/01/2015). Interstate variation in receipt of nephrologist care in US patients approaching ESRD: race, age, and state characteristics. Clin J Am Soc Nephrol 10:1979-1988, 2015 (PMID: 26450930). Clin J Am Soc Nephrol.
  7. Chonchol M, Greene T, Zhang Y, Hoofnagle AN, Cheung AK (01/01/2015). Low vitamin D and high fibroblast growth factor 23 serum levels associate with infectious and cardiac deaths in the HEMO Study. Epub ahead of print (PMID: 25971439). J Am Soc Nephrol.
  8. Zhou G, Liu X, Cheung AK, Huang Y (01/01/2015). Efficacy of aliskiren, compared with angiotensin II blockade, in slowing the progression of diabetic nephropathy in db/db mice: should the combination therapy be a focus?. Am J Transl Res 15:825-840, 2015 (PMID: 26175845). Am J Transplant, (15), 825-840.
  9. Kuttykrishnan S, Kalantar-Zadeh K, Arah OA, Cheung AK, Brunelli S, Heagerty PJ, Katz R, Molnar MZ, Nissenson A, Ravel V, Streja E, Himmelfarb J, Mehrotra R (01/01/2015). Predictors of treatment with dialysis modalities in observational studies for comparative effectiveness research. (PMID: 25883196). Nephrol Dial Transplant, 1208-1217.
  10. Palit S, Chonchol M, Cheung AK, Kaufman J, Smits G, Kendrick J (01/01/2015). Association of BP with death, cardiovascular events, and progression to chronic dialysis in patients with advanced kidney disease. (PMID: 25979975). Clin J Am Soc Nephrol, (10), 934-940.
  11. Jovanovich AJ, Chonchol M, Brady CB, Kaufman JD, Kendrick J, Cheung AK, Jablonski KL (01/01/2014). 25-Vitamin D, 1,25-vitamin D, parathyroid hormone, fibroblast growth factor-23 and cognitive function in men with advanced CKD: A veteran population, (PMID: 25208315). Clin Nephrol, (82), 296-303.
  12. Terry CM, Carlson ML, He Y, Ulu A, Morisseau C, Blumenthal DK, Hammock BD, Cheung AK (01/01/2014). Aberrant soluble epoxide hydrolase and oxylipin levels in a porcine arteriovenous graft stenosis model, (PMID: 25196102). J Vasc Res, (51), 269-282.
  13. Ambrosius WT, Sink KM, Foy CG, Berlowitz DR, Cheung AK, Cushman WC, Fine LJ, Goff DC Jr, Johnson KC, Killeen AA, Lewis CE, Oparil S, Reboussin DM, Rocco MV, Snyder JK, Williamson JD, Wright JT Jr, Whelton PK, The SPRINT Study Research Group (01/01/2014). The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: The Systolic Blood Pressure Intervention Trial (SPRINT). (PMID: 24902920). Clinical Trials, (11), 532-546.
  14. Yan G, Norris KC, Greene T, Yu AJ, Ma JZ, Yu W, Cheung AK (01/01/2014). Race/ethnicity, age, and risk of hospital admission and length of stay during the first year of maintenance hemodialysis, (PMID: 24948142). Clin J Am Soc Nephrol, (9), 1402-1409.
  15. Guo X, Zhou G, Guo M, Cheung AK, Huang Y, Beddhu S (01/01/2014). Adiponectin retards the progression of diabetic nephropathy in db/db mice by counteracting angiotensin II, (PMID: 24744899). Physiol Rep, 2e00230.
  16. Zhang J, Gu C, Lawrence DA, Cheung AK, Huang Y (01/01/2014). A plasminogen activator inhibitor type 1 mutant retards diabetic nephropathy in db/db mice by protecting podocytes. (PMID: 24443353). Exp Physiol, (99), 802-815.
  17. Zhang JL, Morrell G, Rusinek H, Warner L, Vivier PH, Cheung AK, Lerman LO, Lee VS (01/01/2014). : Measurement of renal tissue oxygenation with blood oxygen level-dependent MRI and oxygen transit modeling. (PMID: 24452640). Am J Physiol Renal Physiol, (306), F579-587.
  18. Zhou G, Cheung AK, Liu X, Huang Y (01/01/2014). Valsartan slows the progression of diabetic nephropathy in db/db mice via reduction in podocyte injury and renal oxidative stress and inflammation.(PMID: 24195695). Clin Sci (Lond), (126), 707-720.
  19. Chang, TI, Flythe JE, Brunelli SM, Muntner P, Greene T, Cheung AK, Chertow GM (01/01/2014). Chang, TI, Flythe JE, Brunelli SM, Muntner P, Greene T, Cheung AK, Chertow GM: Visit-to-visit systolic blood pressure variability and outcomes in hemodialysis. (PMID: 23803593). J Hum Hypertens, (28), 18-24.
  20. Dember LM, Imrey PB, Beck GJ, Cheung AK, Himmelfarb J, Huber TS, Kusek JW, Roy-Chaudhury P, Vazquez MA, Alpers CE, Robbin ML, Vita JA, Greene T, Gassman JJ, Feldman HI (01/01/2014). Hemodialysis Fistula Maturation Study Group: Objectives and design of the Hemodialysis Fistula Maturation Study. (PMID: 23992885). Am J Kidney Dis, (63), 104-112.
  21. Yan G, Norris KC, Xin W, Ma JZ, Yu AJ, Greene T, Yu W, Cheung AK (01/01/2013). Facility size, race and ethnicity, and mortality for in-center hemodialysis. (PMID: 23970120). J Am Soc Nephrol, (24), 2062-2070.
  22. Sharma S, Joseph J, Chonchol M, Kaufman JS, Cheung AK, Rafeq Z, Smits G, Kendrick J (01/01/2013). Higher fibroblast growth factor-23 concentrations associate with left ventricular systolic dysfunction in dialysis patients. (PMID: 23849306). Clin Nephrol, (80), 313-321.
  23. Yan G, Norris KC, Yu AJ, Ma JZ, Greene T, Yu W, Cheung AK (01/01/2013). The relationship of age, race and ethnicity with survival in dialysis patients. (PMID: 23539227). Clin J Am Soc Nephrol, (8), 953-961.
  24. Yan G, Cheung AK, Ma JZ, Yu AJ, Greene T, Oliver MN, Yu W, Norris KC (01/01/2013). The associations between race and geographic area and quality-of-care indicators in patients approaching ESRD. (PMID: 23493380). Clin J Am Soc Nephrol, (8), 610-618.
  25. Raphael KL, Zhang Y, Wei G, Greene T, Cheung AK, Beddhu S, El Nahas M (01/01/2013). Serum bicarbonate and mortality in adults in NHANES III. (PMID: 23348878). Nephrol Dial Transplant, (28), 1207-12.
  26. 141 Montford JR, Chonchol M, Cheung AK, Kaufman JS, Greene T, Roberts WL, Smits G, Kendrick J (2013). Low body mass index and dyslipidemia in dialysis patients linked to elevated plasma fibroblast growth factor 23. Am J Nephrol, (37:183-190).
  27. Filipowicz R, Greene T, Wei G, Cheung AK, Raphael KL, Baird BC, Beddhu S (2013). Associations of serum skeletal alkaline phosphatase with elevated C-reactive protein and mortality. Clin J Am Soc Nephrol, 8(1), 26-32.
  28. Sanders WG, Morisseau C, Hammock BD, Cheung AK, Terry CM (2012). Soluble epoxide hydrolase expression in a porcine model of arteriovenous graft stenosis and anti-Inflammatory effects of a soluble epoxide hydrolase inhibitor. Am J Physiol Cell Physiol, Epub ahead, of print.
  29. Kendrick J, Cheung AK, Kaufman JS, Greene T, Roberts WL, Smits G, Chonchol M, HOST Study Investigators (2012). Associations of plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D concentrations with death and progression to maintenance dialysis in patients with advanced kidney disease. Am J Kidney Dis, Epub ahead, of print.
  30. Sanders WG, Hogrebe PC, Grainger DW, Cheung AK, Terry CM (2012). A biodegradable perivascular wrap for controlled, local and directed drug delivery. J Control Release, 161, 81-89.
  31. Terry, CM, Li, L, Li, H, Zhuplatov, I, Blumenthal, DK, Kim, SE, Owen, SC, Kholmovski, EG, Fowers, KD, Rathi, R, Cheung, AK (01012012). In vivo evaluation of the delivery and efficacy of a sirolimus-laden polymer gel for inhibition of hyperplasia in a porcine model of arteriovenoushemodialysis graft stenosis. J Control Release, 160, 459-467.
  32. Sanders WG, Morisseau C, Hammock BD, Cheung AK, Terry CM (2012). Soluble epoxide hydrolase expression in a porcine model of arteriovenous graft stenosis and anti-Inflammatory effects of a soluble epoxide hydrolase inhibitor. Am J Physiol Cell Physiol.
  33. Kendrick J, Cheung AK, Kaufman JS, Greene T, Roberts WL, Smits G, Chonchol MB, and the HOST Investigators (2012). : A biodegradable perivascular wrap for controlled, local and directed drug delivery. Am J Kidney Dis.
  34. Sanders WG, Hogrebe PC, Grainger DW, Cheung AK, Terry CM (2012). A biodegradable perivascular wrap for controlled, local and directed drug delivery. J Control Release, Epub ahead, of print.
  35. Terry CM, Li L, Li H, Zhuplatov I, Blumenthal DK, Kim S-E, Owen SC, Kholmovski EG, Fowers KD, Rathi R, Cheung AK (2012). In vivo evaluation of the delivery and efficacy of a sirolimus-laden polymer gel for inhibition of hyperplasia in a porcine model of arteriovenous hemodialysis graft stenosis. J Control Release, ahead of p.
  36. Jovanovich A, Chonchol M, Cheung AK, Kaufman JS, Greene T, Roberts WL, Smits G, Kendrick J, and the HOST Investigators (2012). Racial differences in markers of mineral metabolism in advanced chronic kidney disease. Clin J Am Soc Nephrol, 7, 640-647.
  37. Brinton, MR, Tagge CA, Stewart RJ, Cheung AK, Shiu YT, Christensen DA (2012). Thermal sensitivity of endothelial cells on synthetic vascular graft material. Int J Hyperthermia, 28, 163-174.
  38. Shastri S, Tangri N, Tighiouart H, Beck GJ, Vlagopoulos P, Ornt D, Eknoyan G, Kusek JW, Herzog C, Cheung AK, Sarnak MJ (2012). Risk factors and a prediction model for sudden cardiac in the HEMO Study. Clin J Am Soc Nephrol, 7, 123-130.
  39. Brinton MR, Stewart RJ, Cheung AK, Christensen DA, Shiu Y-T E (2011). Modelling ultrasound-induced mild hyperthermia of hyperplasia in vascular grafts. Theor Biol Med Model, 8, 42.
  40. Agar BU, Akonu RA, Lo Y-C, Cheung AK, Leypoldt JK (2011). Kinetic model of phosphorus mobilization during and after short and conventional hemodialysis. Clin J Am Soc Nephrol, 6, 2854-2860.
  41. Kendrick J, Cheung AK, Kaufman JS, Greene T, Roberts WL, Smits G, Chonchol M, HOST Investigators (2011). FGF-23 associates with death, cardiovascular events, and initiation of chronic dialysis. J Am Soc Nephrol, 22, 1913-1922.
  42. Agar BU, Akonur A, Cheung AK, Leypoldt JK (2011). A simple method to estimate phosphorus mobilization in hemodialysis using only predialytic and postdialytic blood samples. Hemodial Int, 15, S9-S14.
  43. Tangri N, Shastri S, Tighiouart H, Beck GJ, Cheung AK, Eknoyan G, Sarnak MJ (2011). Beta-blockers for prevention of sudden cardiac death in patients on hemodialysis: A propensity score analysis of the HEMO Study. Am J Kidney Dis, 58, 939-945.
  44. Kopple JD, Cheung AK, Christiansen JS, Djurhuus CB, Nahas ME, Feldt-Rasmussen B, Mitch WE, Wanner C, Gthberg M, T Ikizler TA (2011). OPPORTUNITYTM: A large-scale randomized clinical trial of growth hormone in hemodialysis patients. Nephrol Dial Transplant, 26, 4095-4103.
  45. Chang TI, Shilane D, Brunelli SM, Cheung AK, Chertow GM, Winkelmayer WC (2011). Angiotensin-converting enzyme inhibitors and cardiovascular outcomes in patients on maintenance hemodialysis. Am Heart J, 162, 324-330.
  46. Chang, TI, Paik, J, Greene T, Desai M, Bech F, Cheung AK, Chertow GM (2011). Intradialytic hypotension and vascular access thrombosis. J Am Soc Nephrol, 22, 1526-1533.
  47. Wali RK, Iyengar M, Beck GJ, Chartyan DM, Chonchol M, Lukas MA, Cooper C, Himmelfarb J, Weir MR, Berl T, Henrich WL, Cheung AK (2011). Efficacy and safety of carvedilol in treatment of heart failure in chronic kidney disease: A meta-analysis of randomized trials. Circ Heart Fail, 4, 18-26.
  48. Li L, Blumenthal DK, Terry CM, He Y, Carlson ML, Cheung AK (2011). PDGF-induced proliferation in human arterial and venous smooth muscle cells: molecular basis for differential effects of PDGF isoforms. J Cell Biochem, 112, 289-298.
  49. Chang TI, Friedman GD, Cheung AK, Greene T, Desai M, Chertow GM (2011). Systolic blood pressure and mortality in prevalent haemodialysis patients in the HEMO study. J Hum Hypertens, 25(2), 98-105.
  50. Damera S, Raphael KL, Baird BC, Cheung AK, Greene T, Beddhu S (2011). Serum alkaline phosphatase levels associate with elevated serum C-reactive protein in chronic kidney disease. Kidney Int, 79(2), 228-33.
  51. Huang CX, Tighiouart H, Beddhu S, Cheung AK, Dwyer JT, Eknoyan G, Beck GJ, Levey AS, Sarnak MJ (2010). Both low muscle mass and low fat are associated with higher all-cause mortality in hemodialysis patients. Kidney Int, 77(7), 624-9.
  52. Owen SC, Li H, Sanders WG, Cheung AK, Terry CM (2010). Correlation of tissue drug concentrations with in vivo magnetic resonance images of polymer drug depot around arteriovenous graft. J Control Release, 146(1), 23-30.
  53. Beddhu S, Baird B, Ma X, Cheung AK, Greene T (2010). Serum alkaline phosphatase and mortality in hemodialysis patients. Clin Nephrol, 74(2), 91-6.
  54. Naiman N, Cheung AK, Goldfarb-Rumyantzev AS (2009). Familiality of cardiovascular mortality in end-stage renal disease patients. Am J Nephrol, 29(3), 237-43.
  55. Terry CM, Kim SE, Li L, Goodrich KC, Hadley JR, Blumenthal DK, Parker DL, Cheung AK (2009). Longitudinal assessment of hyperplasia using magnetic resonance imaging without contrast in a porcine arteriovenous graft model. Acad Radiol, 16(1), 96-107.
  56. Preston JS, Tasdizen T, Terry CM, Cheung AK, Kirby RM (2009). Using the stochastic collocation method for the uncertainty quantification of drug concentration due to depot shape variability. IEEE Trans Biomed Eng, 56(3), 609-20.
  57. Goldfarb-Rumyantzev AS, Chelamcharla M, Bray BE, Leypoldt JK, Lavasani I, Nelson N, Lavasani T, Baird B, Cheung AK (2009). Volume indicators and left ventricular mass during aggressive volume management in patients on thrice-weekly hemodialysis. Nephron Clin Pract, 113(4), c270-80.
  58. Beddhu S, Ma X, Baird B, Cheung AK, Greene T (2009). Serum alkaline phosphatase and mortality in African Americans with chronic kidney disease. Clin J Am Soc Nephrol, 4(11), 1805-10.
  59. Zhu W, Masaki T, Cheung AK, Kern SE (2009). In-vitro Release of Rapamycin from a Thermosensitive Polymer for the Inhibition of Vascular Smooth Muscle Cell Proliferation. J Bioequiv Availab, 1, 3-12.
  60. Cheung AK, Greene T, Leypoldt JK, Yan G, Allon M, Delmez J, Levey AS, Levin NW, Rocco MV, Schulman G, Eknoyan G (2008). Association between serum 2-microglobulin level and infectious mortality in hemodialysis patients. Clin J Am Soc Nephrol, 3(1), 69-77.
  61. Cheung AK, Terry C, Li L (2008). Pathogenesis and local drug delivery for prevention of vascular access stenosis. J Ren Nutr, 18(1), 140-5.
  62. Munger MA, Gardner SF, Ateshkadi A, Rabetoy GM, Barri YM, Stoddard GJ, Cheung AK (2008). Misoprostol effects on diclofenac-induced cardiorenal changes in salt-sensitive patients with hypertension: the MEDIC Study. Pharmacotherapy, 28(7), 834-42.
  63. Wald R, Sarnak MJ, Tighiouart H, Cheung AK, Levey AS, Eknoyan G, Miskulin DC (2008). Disordered mineral metabolism in hemodialysis patients: an analysis of cumulative effects in the Hemodialysis (HEMO) Study. Am J Kidney Dis, 52(3), 531-40.
  64. Kopple JD, Cheung AK, Christiansen JS, Djurhuus CB, El Nahas M, Feldt-Rasmussen B, Lange M, Mitch WE, Wanner C, Wiedemann J, Ikizler TA (2008). OPPORTUNITY: a randomized clinical trial of growth hormone on outcome in hemodialysis patients. Clin J Am Soc Nephrol, 3(6), 1741-51.
  65. Chonchol M, Goldenberg I, Moss AJ, McNitt S, Cheung AK (2007). Risk factors for sudden cardiac death in patients with chronic renal insufficiency and left ventricular dysfunction. Am J Nephrol, 27(1), 7-14.
  66. Ramkumar N, Murtaugh MA, Cheung AK, Beddhu S (2007). Lack of synergistic effects of metabolic syndrome and plasma fibrinogen on coronary events and mortality in moderate CKD. Am J Kidney Dis, 49(3), 356-64.
  67. Kuji T, Masaki T, Li L, Cheung AK (2007). Expression of C-reactive protein in myointimal hyperplasia in a porcine arteriovenous graft model. Nephrol Dial Transplant, 22(9), 2469-75.
  68. Li L, Terry CM, Blumenthal DK, Kuji T, Masaki T, Kwan BC, Zhuplatov I, Leypoldt JK, Cheung AK (2007). Cellular and morphological changes during neointimal hyperplasia development in a porcine arteriovenous graft model. Nephrol Dial Transplant, 22(11), 3139-46.
  69. Goldfarb-Rumyantzev AS, Habib AN, Baird BC, Barenbaum LL, Cheung AK (2007). The association of lipid-modifying medications with mortality in patients on long-term peritoneal dialysis. Am J Kidney Dis, 50(5), 791-802.
  70. Beddhu S, Cheung AK, Larive B, Greene T, Kaysen GA, Levey AS, Rocco M, Sarnak M, Toto R, Eknoyan G (2007). Inflammation and inverse associations of body mass index and serum creatinine with mortality in hemodialysis patients. J Ren Nutr, 17(6), 372-80.
  71. Goldfarb-Rumyantzev AS, Leypoldt JK, Nelson N, Kutner NG, Cheung AK (2006). A crossover study of short daily haemodialysis. Nephrol Dial Transplant, 21(1), 166-75.
  72. Zhu W, Masaki T, Bae YH, Rathi R, Cheung AK, Kern SE (2006). Development of a sustained-release system for perivascular delivery of dipyridamole. J Biomed Mater Res B Appl Biomater, 77(1), 135-43.
  73. Delmez JA, Yan G, Bailey J, Beck GJ, Beddhu S, Cheung AK, Kaysen GA, Levey AS, Sarnak MJ, Schwab SJ (2006). Cerebrovascular disease in maintenance hemodialysis patients: results of the HEMO Study. Am J Kidney Dis, 47(1), 131-8.
  74. Cheung AK, Rocco MV, Yan G, Leypoldt JK, Levin NW, Greene T, Agodoa L, Bailey J, Beck GJ, Clark W, Levey AS, Ornt DB, Schulman G, Schwab S, Teehan B, Eknoyan G (2006). Serum beta-2 microglobulin levels predict mortality in dialysis patients: results of the HEMO study. J Am Soc Nephrol, 17(2), 546-55.
  75. Goldfarb-Rumyantzev AS, Hurdle JF, Baird BC, Stoddard G, Wang Z, Scandling JD, Barenbaum LL, Cheung AK (2006). The role of pre-emptive re-transplant in graft and recipient outcome. Nephrol Dial Transplant, 21(5), 1355-64.
  76. Goteti K, Masaki T, Kuji T, Leypoldt JK, Cheung AK, Kern SE (2006). Perivascular tissue pharmacokinetics of dipyridamole. Pharm Res, 23(4), 718-28.
  77. Goldfarb-Rumyantzev AS, Cheung AK, Habib AN, Wang BJ, Lin SJ, Baird BC, Naiman N, Cannon-Albright L (2006). A population-based assessment of the familial component of chronic kidney disease mortality. Am J Nephrol, 26(2), 142-8.
  78. Kuji T, Masaki T, Goteti K, Li L, Zhuplatov S, Terry CM, Zhu W, Leypoldt JK, Rathi R, Blumenthal DK, Kern SE, Cheung AK (2006). Efficacy of local dipyridamole therapy in a porcine model of arteriovenous graft stenosis. Kidney Int, 69(12), 2179-85.
  79. Lee RM, Masaki T, Yang HS, Liu J, Chen J, Li L, Blumenthal DK, Cheung AK (2006). Different signaling responses to anti-proliferative agents in human aortic and venous smooth muscle cells. J Cell Biochem, 99(3), 835-44.
  80. Habib AN, Baird BC, Leypoldt JK, Cheung AK, Goldfarb-Rumyantzev AS (2006). The association of lipid levels with mortality in patients on chronic peritoneal dialysis. Nephrol Dial Transplant, 21(10), 2881-92.
  81. Li L, Blumenthal DK, Masaki T, Terry CM, Cheung AK (2006). Differential effects of imatinib on PDGF-induced proliferation and PDGF receptor signaling in human arterial and venous smooth muscle cells. J Cell Biochem, 99(6), 1553-63.
  82. Thekkedath UR, Chirananthavat T, Leypoldt JK, Cheung AK, Mohammad SF (2006). Elevated fibrinogen fragment levels in uremic plasma inhibit platelet function and expression of glycoprotein IIb-IIIa. Am J Hematol, 81(12), 915-26.
  83. Kwan BC, Beddhu S, Kronenberg F, Cheung AK (2006). Does statin therapy improve cardiovascular outcomes in patients with type 2 diabetes receiving hemodialysis? Nat Clin Pract Nephrol, 2(2), 76-7.
  84. Zhu W, Masaki T, Cheung AK, Kern SE (2006). Cellular pharmacokinetics and pharmacodynamics of dipyridamole in vascular smooth muscle cells. Biochem Pharmacol, 72(8), 956-64.
  85. Terry CM, Blumenthal DK, Sikharam S, Li L, Kuji T, Kern SE, Cheung AK (2006). Evaluation of histological techniques for quantifying haemodialysis arteriovenous (AV) graft hyperplasia. Nephrol Dial Transplant, 21(11), 3172-9.
  86. Zhuplatov SB, Masaki T, Blumenthal DK, Cheung AK (2006). Mechanism of dipyridamole's action in inhibition of venous and arterial smooth muscle cell proliferation. Basic Clin Pharmacol Toxicol, 99(6), 431-9.
  87. Kim S-J, Masaki T, Rowley R, Leypoldt JK, Mohammad SF, Cheung AK (2005). Different responses by cultured aortic and venous smooth muscle cells to radiation. Kidney Int, 68, 371-377.
  88. Goldfarb-Rumyantzev AS, Baird BC, Leypoldt JK, Cheung AK (2005). The association between BP and mortality in patients on chronic peritoneal dialysis. Nephrol Dial Transplant, 20(8), 1693-701.
  89. Beddhu S, Kimmel PL, Ramkumar N, Cheung AK (2005). Associations of metabolic syndrome with inflammation in CKD: results From the Third National Health and Nutrition Examination Survey (NHANES III). Am J Kidney Dis, 46(4), 577-86.
  90. Ramkumar N, Beddhu S, Eggers P, Pappas LM, Cheung AK (2005). Patient preferences for in-center intense hemodialysis. Hemodial Int, 9(3), 281-95.
  91. Chelamcharla M, Leypoldt JK, Cheung AK (2005). Dialyzer membranes as determinants of the adequacy of dialysis. Semin Nephrol, 25(2), 81-9.
  92. Goldfarb-Rumyantzev A, Hurdle JF, Scandling J, Wang Z, Baird B, Barenbaum L, Cheung AK (2005). Duration of end-stage renal disease and kidney transplant outcome. Nephrol Dial Transplant, 20(1), 167-75.
  93. Rocco MV, Cheung AK, Greene T, Eknoyan G (2005). The HEMO Study: applicability and generalizability. Nephrol Dial Transplant, 20(2), 278-84.
  94. Depner TA, Greene T, Daugirdas JT, Cheung AK, Gotch FA, Leypoldt JK (2004). Dialyzer performance in the HEMO Study: in vivo K0A and true blood flow determined from a model of cross-dialyzer urea extraction. ASAIO J, 50(1), 85-93.
  95. Cheung AK, Sarnak MJ, Yan G, Berkoben M, Heyka R, Kaufman A, Lewis J, Rocco M, Toto R, Windus D, Ornt D, Levey AS (2004). Cardiac diseases in maintenance hemodialysis patients: results of the HEMO Study. Kidney Int, 65(6), 2380-9.
  96. Masaki T, Kamerath CD, Kim SJ, Leypoldt JK, Mohammad SF, Cheung AK (2004). In vitro pharmacological inhibition of human vascular smooth muscle cell proliferation for the prevention of hemodialysis vascular access stenosis. Blood Purif, 22(3), 307-12.
  97. Kim SJ, Masaki T, Leypoldt JK, Kamerath CD, Mohammad SF, Cheung AK (2004). Arterial and venous smooth-muscle cells differ in their responses to antiproliferative drugs. J Lab Clin Med, 144(3), 156-62.
  98. Leypoldt JK, Cheung AK, Deeter RB, Goldfarb-Rumyantzev A, Greene T, Depner TA, Kusek J (2004). Kinetics of urea and beta-microglobulin during and after short hemodialysis treatments. Kidney Int, 66(4), 1669-76.
  99. Ramkumar N, Cheung AK, Pappas LM, Roberts WL, Beddhu S (2004). Association of obesity with inflammation in chronic kidney disease: a cross-sectional study. J Ren Nutr, 14(4), 201-7.
  100. Masaki T, Rathi R, Zentner G, Leypoldt JK, Mohammad SF, Burns GL, Li L, Zhuplatov S, Chirananthavat T, Kim SJ, Kern S, Holman J, Kim SW, Cheung AK (2004). Inhibition of neointimal hyperplasia in vascular grafts by sustained perivascular delivery of paclitaxel. Kidney Int, 66(5), 2061-9.
  101. 68 Zebrack JS, Anderson JL, Beddhu S, Horne BD, Bair TL, Cheung A, Muhlestein JB for the Intermountain Heart Collaborative Study Group (2003). Do Associations with C-reactive protein and extent of coronary artery disease account for the increased cardiovascular risk of renal insufficiency? J Am Coll Cardiol, 42, 57-63.
  102. Leypoldt JK, Cheung AK, Chirananthavat T, Gilson JF, Kamerath CD, Deeter RB (2003). Hollow fiber shape alters solute clearances in high flux hemodialyzers. ASAIO J, 49(1), 81-7.
  103. Beddhu S, Samore MH, Roberts MS, Stoddard GJ, Pappas LM, Cheung AK (2003). Creatinine production, nutrition, and glomerular filtration rate estimation. J Am Soc Nephrol, 14(4), 1000-5.
  104. Beddhu S, Samore MH, Roberts MS, Stoddard GJ, Ramkumar N, Pappas LM, Cheung AK (2003). Impact of timing of initiation of dialysis on mortality. J Am Soc Nephrol, 14(9), 2305-12.
  105. Cheung AK, Levin NW, Greene T, Agodoa L, Bailey J, Beck G, Clark W, Levey AS, Leypoldt JK, Ornt DB, Rocco MV, Schulman G, Schwab S, Teehan B, Eknoyan G (2003). Effects of high-flux hemodialysis on clinical outcomes: results of the HEMO study. J Am Soc Nephrol, 14(12), 3251-63.
  106. Leypoldt JK, Cheung AK, Delmez JA, Gassman JJ, Levin NW, Lewis JA, Lewis JL, Rocco MV (2002). Relationship between volume status and blood pressure during chronic hemodialysis. Kidney Int, 61(1), 266-75.
  107. Bergstrom J, Lysaght M, Cheung AK (2002). The career of Lee W. Henderson. J Am Soc Nephrol, 13 Suppl 1, S1-2.
  108. Leypoldt JK, Cheung AK (2002). Optimal use of hemodialyzers. Contrib Nephrol, (137), 129-37.
  109. Cheung AK, Yan G, Greene T, Daugirdas JT, Dwyer JT, Levin NW, Ornt DB, Schulman G, Eknoyan G (2002). Seasonal variations in clinical and laboratory variables among chronic hemodialysis patients. J Am Soc Nephrol, 13(9), 2345-52.
  110. Beddhu S, Kaysen GA, Yan G, Sarnak M, Agodoa L, Ornt D, Cheung AK (2002). Association of serum albumin and atherosclerosis in chronic hemodialysis patients. Am J Kidney Dis, 40(4), 721-7.
  111. Beddhu S, Allen-Brady K, Cheung AK, Horne BD, Bair T, Muhlestein JB, Anderson JL (2002). Impact of renal failure on the risk of myocardial infarction and death. Kidney Int, 62(5), 1776-83.
  112. Goldfarb-Rumyantzev AS, Cheung AK, Leypoldt JK (2002). Computer simulation of small-solute and middle-molecule removal during short daily and long thrice-weekly hemodialysis. Am J Kidney Dis, 40(6), 1211-8.
  113. Eknoyan G, Beck GJ, Cheung AK, Daugirdas JT, Greene T, Kusek JW, Allon M, Bailey J, Delmez JA, Depner TA, Dwyer JT, Levey AS, Levin NW, Milford E, Ornt DB, Rocco MV, Schulman G, Schwab SJ, Teehan BP, Toto R (2002). Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med, 347(25), 2010-9.
  114. Rocco MV, Yan G, Heyka RJ, Benz R, Cheung AK (2001). Risk factors for hypertension in chronic hemodialysis patients: baseline data from the HEMO study. Am J Nephrol, 21(4), 280-8.
  115. Leypoldt JK, Cheung AK (2001). Increases in mass transfer-area coefficients and urea Kt/V with increasing dialysate flow rate are greater for high-flux dialyzers. Am J Kidney Dis, 38(3), 575-9.
  116. Peng H, Cheung AK, Reimer LG, Kamerath CD, Leypoldt JK (2001). Effect of indomethacin on peritoneal protein loss in a rabbit model of peritonitis. Kidney Int, 59(1), 44-51.
  117. Kozek-Langenecker SA, Mohammad SF, Masaki T, Green W, Kamerath C, Cheung AK (2000). The effects of aprotonin on platelets in vitro using whole blood flow cytometry. Anesth Analg, 90(1), 12-6.
  118. Kozek-Langenecker SA, Mohammad SF, Masaki T, Kamerath C, Cheung AK (2000). The effects of heparin, protamine, and heparinase 1 on platelets in vitro using whole blood flow cytometry. Anesth Analg, 90(4), 808-12.
  119. Luo Q, Cheung AK, Kamerath CD, Reimer LG, Leypoldt JK (2000). Increased protein loss during peritonitis associated with peritoneal dialysis is neutrophil dependent. Kidney Int, 57(4), 1736-42.
  120. Munger MA, Ateshkadi A, Cheung AK, Flaharty KK, Stoddard GJ, Marshall EH (2000). Cardiopulmonary events during hemodialysis: effects of dialysis membranes and dialysate buffers. Am J Kidney Dis, 36(1), 130-9.
  121. Cheung AK, Sarnak MJ, Yan G, Dwyer JT, Heyka RJ, Rocco MV, Teehan BP, Levey AS (2000). Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients. Kidney Int, 58(1), 353-62.
  122. Leypoldt JK, Cheung AK (1999). The effect of low dialysate flow rate on hemodialyzer mass transfer-area coefficients of urea and creatinine. Home Hemodial Int, 3, 51-54.
  123. Leypoldt JK, Cheung AK, Carroll CE, Stannard DC, Pereira BJG, Agodoa LY, Port FK (1999). Effect of dialysis membranes and middle molecule removal on chronic hemodialysis patient survival. Am J Kidney Dis, 33, 349-355.
  124. Cheung AK, Agodoa LY, Clark W, Daugirdas, JT, Depner TA, Gotch FA, Greene T, Levin NW, Leypoldt JK, and the Hemodialysis HEMO Study (1999). Effects of hemodialyzer reuse on clearances of urea and ß2-microglobulin. J Am Soc Nephrol, 10, 117-127.
  125. Masaki T, Gilson J, Leypoldt JK, Cheung AK (1999). Effect of permeability on indices of haemodialysis membrane biocompatibility. Nephrol Dial Transplant, 14(5), 1176-81.
  126. Kozek-Langenecker SA, Masaki T, Mohammad H, Green W, Mohammad SF, Cheung AK (1999). Fibrinogen fragments and platelet dysfunction in uremia. Kidney Int, 56(1), 299-305.
  127. Yarar D, Cheung AK, Sakiewicz P, Lindsay RM, Paganini EP, Steuer RR, Leypoldt JK (1999). Ultrafiltration method for measuring vascular access flow rates during hemodialysis. Kidney Int, 56(3), 1129-35.
  128. Leypoldt JK, Cheung AK, Deeter RB (1999). Rebound kinetics of beta2-microglobulin after hemodialysis. Kidney Int, 56(4), 1571-7.
  129. Steuer RR, Germain MJ, Leypoldt JK, Cheung AK (1998). Enhanced fluid removal guided by blood volume monitoring during chronic hemodialysis. Artif Organs, 22(8), 627-32.
  130. Leypoldt JK, Cheung AK, Deeter RB (1998). Effect of hemodialyzer reuse: dissociation between clearances of small and large solutes. Am J Kidney Dis, 32(2), 295-301.
  131. Ing TS, Cheung AK, Golper TA, Lang GR, Lazarus JM, Letteri JM, Levin NW, Lundin AP, Molony DA, Mujais SK, Port FK, Ward RA (1997). National Kidney Foundation report on dialyzer reuse. Am J Kidney Dis, 30, 859-871.
  132. Cheung AK, Leypoldt JK (1997). The hemodialysis membranes: a historical perspective, current state and future prospect. Semin Nephrol, 17(3), 196-213.
  133. Leypoldt JK, Cheung AK, Agodoa LY, Daugirdas JT, Greene T, Keshaviah PR (1997). Hemodialyzer mass transfer-area coefficients for urea increase at high dialysate flow rates. The Hemodialysis (HEMO) Study. Kidney Int, 51(6), 2013-7.
  134. Morton KA, Pisani DE, Whiting JH Jr, Cheung AK, Arias JM, Valdivia S (1997). Determination of glomerular filtration rate using technetium-99m-DTPA with differing degrees of renal function. J Nucl Med Technol, 25(2), 110-4.
  135. Moser L, Callahan KS, Cheung AK, Stoddard GJ, Munger MA (1997). ACE inhibitor effects on platelet function in stages I-II hypertension. J Cardiovasc Pharmacol, 30(4), 461-7.
  136. Leypoldt JK, Cheung AK, Deeter RB (1997). Single compartment models for evaluating beta 2-microglobulin clearance during hemodialysis. ASAIO J, 43(6), 904-9.
  137. Leypoldt JK, Cheung AK (1996). Removal of high-molecular-weight solutes during high-efficiency and high-flux haemodialysis. Nephrol Dial Transplant, 11(2), 329-35.
  138. Steuer RR, Leypoldt JK, Cheung AK, Senekjian HO, Conis JM (1996). Reducing symptoms during hemodialysis by continuously monitoring the hematocrit. Am J Kidney Dis, 27(4), 525-32.
  139. Cheung AK, Parker CJ, Ren K, Iverius PH (1996). Increased lipase inhibition in uremia: identification of pre-beta-HDL as a major inhibitor in normal and uremic plasma. Kidney Int, 49(5), 1360-71.
  140. Leypoldt JK, Cheung AK, Steuer RR, Harris DH, Conis JM (1995). Determination of circulating blood volume by continuously monitoring hematocrit during hemodialysis. J Am Soc Nephrol, 6(2), 214-9.
  141. Leypoldt JK, Charney DI, Cheung AK, Naprestek CL, Akin BH, Shockley TR (1995). Ultrafiltration and solute kinetics using low sodium peritoneal dialysate. Kidney Int, 48(6), 1959-66.
  142. Cheung AK, Faezi-Jenkin B, Leypoldt JK (1994). Effect of thrombosis on complement activation and neutrophil degranulation during in vitro hemodialysis. J Am Soc Nephrol, 5(1), 110-5.
  143. Steuer RR, Leypoldt JK, Cheung AK, Harris DH, Conis JM (1994). Hematocrit as an indicator of blood volume and a predictor of intradialytic morbid events. ASAIO J, 40(3), M691-6.
  144. Cheung AK, Parker CJ, Hohnholt M (1994). Soluble complement receptor type 1 inhibits complement activation induced by hemodialysis membranes in vitro. Kidney Int, 46(6), 1680-7.
  145. Cheung AK, Parker CJ, Hohnholt M (1993). Beta2 integrins are required for neutrophil degranulation induced by hemodialysis membranes. Kidney Int, 43(3), 649-60.
  146. Cheung AK, DeVault GA Jr, Gregory MC (1993). A prospective study on treatment of hypercholesterolemia with lovastatin in renal transplant patients receiving cyclosporine. J Am Soc Nephrol, 3(12), 1884-91.
  147. Cheung AK, Wu LL, Kablitz C, Leypoldt JK (1993). Atherogenic lipids and lipoproteins in hemodialysis patients. Am J Kidney Dis, 22(2), 271-6.
  148. Leypoldt JK, Gilson JF, Blindauer KM, Cheung AK (1992). Macromolecule adsorption to hemodialysis membranes depends on molecular size. Blood Purif, 10(1), 53-60.

Review

  1. Chertow GM, Beddhu S, Lewis J, Toto RD, Cheung AK (01/01/2014). Managing hypertension in patients with chronic kidney disease: a marathon, not a “SPRINT”. in press. [Review]. Journal of the American Society of Nephrology.
  2. Levey AS, Inker LA, Matsushita K, Greene T, Willis K, Lewis E, de Zeeuw D, Cheung AK, Coresh J (01/01/2014). GFR decline as an end point for clinical trials in CKD: A scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration, 64:821-835 (PMID: 25441437). [Review]. American Journal of Kidney Diseases.
  3. Isakova T, Ix JH, Sprague SM, Raphael KL Fried L, Gassman JJ, Raj D, Cheung AK, Kusek JW, Flessner MF, Wolf M, Block GA (01/01/2014). Rationale and approaches to phosphate and fibroblast growth factor 23 reduction in CKD. , in press (PMID: 25967123). [Review]. Journal of the American Society of Nephrology.
  4. Zhang JL, Morrell G, Rusinek H, Sigmund EE, Chandarana H, Lerman LO, Prasad PV, Niles D, Artz N, Fain S, Vivier PH, Cheung AK, Lee VS (01/01/2014). New magnetic resonance imaging methods in nephrology, 85:768-778, (PMID: 24067433). [Review]. Kidney International.
  5. Palevsky PM, Molitoris BA, Okusa MD, Levin A, Waikar SS, Wald R, Chertow GM, Murray PT, Parikh CR, Shaw AD, Go AS, Faubel SG, Kellum JA, Chinchilli VM, Liu KD, Cheung AK, Weisbord SD, Chawla LS, Kaufman JS, Devarajan P, Toto RM, Hsu CY, Greene T, Mehta RL, Stokes JB, Thompson AM, Thompson BT, Westenfelder CS, Tumlin JA, Warnock DG, Shah SV, Xie Y, Duggan EG, Kimmel PL, Star RA (01/01/2012). Design of clinical trials in acute kidney injury: Report from an NIDDK Workshop on trial methodology. 7:844-850, (PMID: 22442182). [Review]. Clinical Journal of the American Society of Nephrology.
  6. Molitoris BA, Okusa MD, Palevsky PM, Chawla LS, Kaufman JS, Devarajan P, Toto RM, Hsu CY, Greene TH, Faubel SG, Kellum JA, Wald R, Chertow GM, Levin A, Waikar SS, Murray PT, Parikh CR, Shaw AD, Go AS, Chinchilli VM, Liu KD, Cheung AK, Weisbord SD, Mehta RL, Stokes JB, Thompson AM, Thompson BT, Westenfelder CS, Tumlin JA, Warnock DG, Shah SV, Xie Y, Duggan EG, Kimmel PL, Star RA (01/01/2012). Design of clinical trials in AKI: A Report from an NIDDK Workshop. Trials of patients with sepsis and in selected hospital settings.7:856-860,(PMID: 22442184). [Review]. Clinical Journal of the American Society of Nephrology.
  7. Palevsky PM, Molitoris BA, Okusa MD, Levin A, Waikar SS, Wald R, Chertow GM, Murray PT, Parikh CR, Shaw AD, Go AS, Faubel SG, Kellum JA, Chinchilli VM, Liu KD, Cheung AK, Weisbord SD, Chawla LS, Kaufman JS, Devarajan P, Toto RM, Hsu CY, Greene T, Mehta RL, Stokes JB, Thompson AM, Thompson BT, Westenfelder CS, Tumlin JA, Warnock DG, Shah SV, Xie Y, Duggan EG, Kimmel PL, Star RA (2012). Design of clinical trials in acute kidney injury: Report from an NIDDK Workshop on trial methodology. [Review]. Clinical Journal of the American Society of Nephrology, Epub ahead, of print.
  8. Molitoris BA, Okusa MD, Palevsky PM, Chawla LS, Kaufman JS, Devarajan P, Toto RM, Hsu CY, Greene TH, Faubel SG, Kellum JA, Wald R, Chertow GM, Levin A, Waikar SS, Murray PT, Parikh CR, Shaw AD, Go AS, Chinchilli VM, Liu KD, Cheung AK, Weisbord SD, Mehta RL, Stokes JB, Thompson AM, Thompson BT, Westenfelder CS, Tumlin JA, Warnock DG, Shah SV, Xie Y, Duggan EG, Kimmel PL, Star RA (2012). Design of clinical trials in AKI: A Report from an NIDDK Workshop. Trials of patients with sepsis and in selected hospital settings. [Review]. Clinical Journal of the American Society of Nephrology, Epub ahead, of print.
  9. Okusa MD, Molitoris BA, Palevsky PM, Chinchilli VM, Liu KD, Cheung AK, Weisbord SD, Faubel S, Kellum JA, Wald R, Chertow GM, Levin A, Waikar SS, Murray PT, Parikh CR, Shaw AD, Go AS, Chawla LS, Kaufman JS, Devarajan P, Toto RM, Hsu CY, Greene TH, Mehta RL, Stokes JB, Thompson AM, Thompson BT, Westenfelder CS, Tumlin JA, Warnock DG, Shah SV, Xie Y, Duggan EG, Kimmel PL, Star RA (2012). Design of clinical trials in acute kidney injury: A report from an NIDDK Workshop – prevention trials. [Review]. Clinical Journal of the American Society of Nephrology, Epub ahead, of print.
  10. Raphael KL, Cheung AK (2011). Implications of the Frequent Hemodialysis Network-Daily Trial. [Review]. Seminars in Dialysis, 24, 621-628.
  11. Redon J, Martinez F, Cheung AK (2010). Special considerations for antihypertensive agents in dialysis patients. [Review]. Blood Purif, 29(2), 93-8.
  12. Cheung AK (2009-present). Contributing author on several topics. [Review]. UpToDate Clinical Reference Library.
  13. Cheung AK (2009). Is lipid control necessary in hemodialysis patients? [Review]. Clin J Am Soc Nephrol, 4 Suppl 1, S95-101.
  14. Li L, Terry CM, Shiu YT, Cheung AK (2008). Neointimal hyperplasia associated with synthetic hemodialysis grafts. [Review]. Kidney Int, 74(10), 1247-61.
  15. Kwan BC, Kronenberg F, Beddhu S, Cheung AK (2007). Lipoprotein metabolism and lipid management in chronic kidney disease. [Review]. J Am Soc Nephrol, 18(4), 1246-61.
  16. Leypoldt JK, Cheung AK (2006). Revisiting the hemodialysis dose. [Review]. Semin Dial, 19(2), 96-101.
  17. Roy-Chaudhury P, Sukhatme VP, Cheung AK (2006). Hemodialysis vascular access dysfunction: a cellular and molecular viewpoint. [Review]. J Am Soc Nephrol, 17(4), 1112-27.
  18. Nissenson AR, Agarwal R, Allon M, Cheung AK, Clark W, Depner T, Diaz-Buxo JA, Kjellstrand C, Kliger A, Martin KJ, Norris K, Ward R, Wish J (2004). Improving outcomes in CKD and ESRD patients: carrying the torch from training to practice. [Review]. Semin Dial, 17(5), 380-97.
  19. Henderson LW, Clark WR, Cheung AK (2001). Quantification of middle molecular weight solute removal in dialysis. [Review]. Semin Dial, 14(4), 294-9.
  20. Leypoldt JK, Cheung AK (1999). Extracellular volume in nocturnal hemodialysis. [Review]. Semin Dial, 12, S50-S54.
  21. Cheung AK, Leypoldt JK (1998). Evaluation of hemodialyzer performance. [Review]. Semin Dial, 11, 131-137.
  22. Leypoldt JK, Cheung AK (1998). Evaluating volume status in hemodialysis patients. [Review]. Adv Ren Replace Ther, 5(1), 64-74.
  23. Cheung AK (1996). Stages of future technological developments in haemodialysis. [Review]. Nephrol Dial Transplant, 11 Suppl 8, 52-8.
  24. Leypoldt JK, Cheung AK (1996). Characterization of molecular transport in artificial kidneys. [Review]. Artif Organs, 20(5), 381-9.
  25. Charney DI, Walton DF, Cheung AK (1994). Difficult management problems in dialysis: Impotence II. [Review]. Semin Dial, 7, 22-29.
  26. Cheung AK (1994). Quantitation of dialysis. The importance of membrane and middle molecules. [Review]. Blood Purif, 12(1), 42-53.
  27. Cheung AK, Lemke H (1994). Criteria and standardization for biocompatibility. [Review]. Nephrol Dial Transplant, 9 Suppl 2, 72-6.
  28. Cheung AK (1994). Complement activation as index of haemodialysis membrane biocompatibility: the choice of methods and assays. [Review]. Nephrol Dial Transplant, 9 Suppl 2, 96-103.
  29. Cheung AK (1993). Interactions between plasma proteins and hemodialysis membranes. [Review]. Adv Nephrol Necker Hosp, 22, 417-37.
  30. Charney DI, Walton DF, Cheung AK (1993). Atherosclerosis in chronic renal failure. [Review]. Curr Opin Nephrol Hypertens, 2(6), 876-82.
  31. Cheung AK (1992). Clinical phenomena induced by complement and leukocyte interactions with artificial surfaces. [Review]. J Clin Apheresis, 7(3), 147-8.

Book Chapter

  1. Leypoldt JK, Henderson LW, Cheung AK (in press). Middle molecules. In Ing TS, Rahman M, Kjellstrand CM (Eds.), Dialysis: History, Development and Promise. New Jersey: World Scientific Publishing.
  2. Leypoldt JK, Culleton BF, Cheung AK (2010). Hemodialysis adequacy. In Himmelfarb J, Sayegh MH (Eds.), Chronic Kidney Disease, Dialysis, and Transplantation: Companion to Brenner & Rector’s The Kidney (3rd, pp. 320-334). Philadelphia: Elsevier.
  3. Reddy B, Cheung AKH (2009). Hemodialysis. In Lai KN (Ed.), A Practical Manual of Renal Medicine: Nephrology, Dialysis and Transplantation (pp. 201-223). Imperial College Press and World Scientific Publisher.
  4. Ford L, Ward RA, Cheung AK (2009). Choice of the hemodialysis membrane. In Henrich WL (Ed.), Principles and Practice of Dialysis (4th, pp. 1-11). Philadelphia: Lippincott Williams & Wilkins.
  5. Cheung, AK (2009). Hemodialysis and hemofiltration. In Greenberg A, Cheung AK, Coffman TM, Falk RJ, Jennette JC (Eds.), National Kidney Foundation Primer on Kidney Diseases (5th, pp. 446-458). Philadelphia: Saunders Elsevier.
  6. Wali R, Kaluvapalle JR, Cheung AK (2008). Complications associated with hemodialysis. In Wilcox CS (Ed.), Therapy in Nephrology and Hypertension (Companion to Brenner & Rector’s The Kidney) (3rd edition, pp. 891-912). Philadelphia: Elsevier Saunders.
  7. Cheung AK (2005). Hemodialysis and hemofiltration. In Greenberg A, Cheung AK, Coffman TM, Falk RJ, Jennette JC. Saunders (Eds.), National Kidney Foundation Primer on Kidney Diseases (4th edition, pp. 464-476). Philadelphia: Elsevier.
  8. Greene T, Cheung AK, Krediet R (2001). : The design of randomized clinical trials in dialysis patients. In Horl WH, Koch KM, Lindsay RM, Ronco C, Winchester JF (Eds.), Replacement of Renal Function by Dialysis (5th, pp. 1521-1542). Dordrecht/Boston/London: Kluwer Academic Press.
  9. Cheung AK (2001). Hemodialysis and hemofiltration. In: National Kidney Foundation Primer on Kidney Diseases. In Greenberg A, Cheung AK, Coffman TM, Falk RJ, Jennette JC (Eds.), National Kidney Foundation Primer on Kidney Diseases (3rd, pp. 396-404). San Diego: Academic Press.
  10. Pereira BJG, Cheung AK (2000). Complications of biocompatibility of hemodialysis membranes. In Lameire NH, Mehta RL (Eds.), Complications of Dialysis (pp. 41-68). New York: Marcel Dekker.
  11. Pereira BG, Cheung AK (2000). Biocompatibility of hemodialysis membrane. In Owen WF, Pereira BJG, Sayegh MH (Eds.), Dialysis and Transplantation: A Companion to Brenner & Rector's The Kidney (pp. 32-56). Philadelphia: WB Saunders.
  12. Ambalavanan S, Rabetoy G, Cheung A (1999). High efficiency and high flux hemodialysis. In Schrier RW (Ed.), Atlas of diseases of the kidney (3, pp. 1-3.10). Philadelphia.
  13. Leypoldt JK, Cheung AK Fluid removal during hemodialysis (1999). Fluid removal during hemodialysis. In Leypoldt JK. RG Landes (Ed.), The Artificial Kidney: Physiological modeling and tissue engineering (pp. 1-23).
  14. Leypoldt JK, Cheung AK (1998). Dialyzer reprocessing and solute clearances. In Association for the Advancement of Medical Instrumentation Standards and Recommended Practices (3, pp. 333-339).
  15. Cheung AK (1998). Hemodialysis and hemofiltration. In Greenberg A, Cheung AK, Coffman TM, Falk RJ, Jennette JC (Eds.), National Kidney Foundation Primer on Kidney Diseases (2nd, pp. 408-415). San Diego: Academic Press.
  16. Cheung AK, Mohammad SF, Leypoldt JK (1997). Adhesion molecules and artificial membranes. In Paul LC, Issekutz TB (Eds.), Targetting cell adhesion molecules for therapeutic application (pp. 643-678). New York.
  17. Walton DF, Cheung AK (1997). Membrane biocompatibility. In Suki WN, Massry SG (Eds.), Therapy of renal diseases and related disorders (3rd, pp. 1029-1042). Kluwer Academic Publishers.
  18. Walton DF, Cheung AK (1995). Membrane biocompatibility. In Nissenson AR, Fine RN, Gentile DE (Eds.), Clinical dialysis (3rd). Norwalk: Appleton & Lange.
  19. Cheung AK (1994). Hemodialysis and hemofiltration. In Greenberg A, Cheung AK, Coffman TM, Falk RJ, Jennette JC (Eds.), National Kidney Foundation Primer on Kidney Diseases (1, pp. 258-265). San Diego: Academic Press.
  20. Cheung AK (1993). Dialyzer biocompatibility: Practical considerations. In Nissenson AR, Fine RN (Eds.), Dialysis Therapy (2nd, pp. 75-77). Hanley & Belfus, Inc.

Case Report

  1. Loghman-Adham M, Walton D, Iverius PH, Deiss A, Knight JA, Cheung AK (1997). Spurious hypophosphatemia in a patient with multiple myeloma. Am J Kidney Dis, 30(4), 571-5.
  2. Beckwith C, Flaharty KK, Cheung AK, Beatty PG (1993). Fanconi's syndrome due to ifosfamide. Bone Marrow Transplant, 11(1), 71-3.

Editorial

  1. Chang TI, Cheung AK, Chertow GM (2010). Blood pressure control in type 2 diabetes mellitus. Am J Kidney Dis, 56(6), 1029-31.
  2. Cheung AK, Greene T (2009). Effect of membrane permeability on survival of hemodialysis patients. J Am Soc Nephrol, 20(3), 462-4.
  3. Henderson LW, Leypoldt JK, Lysaght MJ, Cheung AK (1997). Death on dialysis and the time/flux trade-off. Blood Purif, 15(1), 1-14.
  4. Cheung AK (1994). Biocompatibility of Dialysis membrane: Practical considerations. International Yearbook of Nephrology Dialysis Transplantation, 139-149.

Other

  1. Cheung AK, Ward RA (2011). ASN Renal Weekends slide set, American Society of Nephrology. ASN Renal Weekends slide set. American Society of Nephrology.
  2. Levin NW, Kotanko P, Eckardt KU, Kasiske BL, Chazot C, Cheung AK, Redon J, Wheeler DC, Zoccali C, London GM (2010). Blood pressure in chronic kidney disease stage 5D-report from a Kidney Disease: Improving Global Outcomes controversies conference. Kidney Int (77(4), pp. 273-84). United States.

Clinical Trials

Clinical Trials

Video & News